This research article from the Annals of Internal Medicine presents a post hoc analysis of the SURMOUNT-1 trial, focusing on the relationship between tirzepatide-induced weight reductionand improvements in cardiometabolic risk factors in adults with obesity. The study examined how various degrees of weight loss (from less than 5% to 35% or more) influenced changes in waist circumference, blood pressure, lipid levels, and glycemic markers over 72 weeks. The findingssuggest that greater weight reduction generally correlated with more significant improvementsacross most cardiometabolic health indicators, though the pattern of improvement varied for different factors. For instance, hemoglobin A1c showed benefits even with modest weight loss, while lipid improvements were primarily observed with weight reductions exceeding 10%.